Straumann (company)
| Straumann Holding AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0012280076 |
| founding | 1954 |
| Seat |
Basel , Switzerland
|
| management |
|
| Number of employees | 7,590 (Q4 2019) |
| sales | 1.596 billion CHF (2019) |
| Branch | Medical technology |
| Website | www.straumann-group.com |
| As of January 1, 2020 | |
The Straumann Holding AG , based in Basel is an internationally active Swiss company in implant and restorative dental prostheses and oral tissue regeneration. In the 2019 financial year, the group of companies employed around 7,600 people and generated sales of around 1.6 billion Swiss francs. Straumann Holding is listed on the Swiss stock exchange SIX Swiss Exchange listed .
Field of activity
Straumann is through the acquisition of etkon , a leader in CAD / CAM tooth prosthetics , entered the market of restorative dentistry. This enables Straumann to offer surgical, restorative and regenerative solutions ranging from bone formation and tissue regeneration to dental implants and prosthetics to customized crowns and bridges.
In collaboration with clinics, research institutes and universities, the company researches and develops implants, instruments and tissue regeneration products for dental prosthesis solutions and to prevent tooth loss.
In addition, Straumann also offers training and services for dental professionals, including training and education conducted in collaboration with the International Team for Implantology (ITI).
history
The history of the Straumann Group is divided into three sections and spans more than half a century. It began in 1954 in Waldenburg, Switzerland, with the research institute, which was named after its founder Reinhard Straumann Research Institute Dr. Ing.R. Straumann AG was named.
1954-1970
Between 1954 and 1970 the company specialized in metal alloys for watchmaking and material testing . Straumann's significant inventions of these years include special alloys that are still used in watch springs today ( Nivarox ). A breakthrough in the use of non-corrosive alloys in the treatment of bone fractures prompted Fritz Straumann to become involved in orthopedics and implantology and ushered in the second phase in the company's history.
The “Swiss Working Group for Osteosynthesis Issues”, which has existed for two years, was looking for a company capable of supplying materials for osteosynthesis implants. Fritz Straumann, the son of the company founder, got in touch in 1960.
1970-1990
Between 1970 and 1990 Straumann became the leading manufacturer of osteosynthesis implants. A management buy-out of the Osteosynthesis division in 1990 led to the founding of Stratec (later Synthes). This was also the hour of birth of the company in its current form. Thomas Straumann, grandson of the founder, with the remaining 25 people concentrated exclusively on dental implantology . Originally, Thomas Straumann intended to set up his own company. But his father's early death prompted him to join the family business anyway. The 1980s were characterized by geographical expansion with the establishment of branches in Germany (1980) and in the USA (1989).
From 1974 the first dental implants were developed at the Straumann Institute and successfully clinically tested at the University of Bern. The International Team for Implantology (ITI) was founded in 1980 under the leadership of Fritz Straumann, Waldenburg, and André Schroeder, University of Bern . Straumann entered into a partnership with the ITI.
Since 1998
Straumann Holding AG became a public company in 1998 and its shares have been listed on the Swiss stock exchange ever since . In 2000, a production facility in Villeret , Bernese Jura, and a technology center in Waldenburg were opened. Straumann acquired Kuros Therapeutics AG in 2002 and entered the biomaterials sector . In 2003 Straumann acquired the Swedish company Biora , a pioneer in the biologically based regeneration of dental tissue. The main product is Emdogain® from the field of oral tissue regeneration. In 2004 the Straumann Group moved to its new headquarters in Basel.
organization
Source: Straumann Group, 2019 Annual Report
Board of Directors
- Gilbert Achermann - Chairman of the Board of Directors
- Thomas Straumann - Vice Chairman of the Board of Directors, Member of the Compensation Committee
- Monique Bourquin - Member of the Compensation Committee
- Sebastian Burckhardt - Member of the Audit Committee, Secretary of the Board of Directors
- Ulrich Looser - Chairman of the Compensation Committee
- Beat Lüthi - Chairman of the Audit Committee
- Regula Wallimann - member of the Audit Committee
Management
- Guillaume Daniellot - Chief Executive Officer
- Gerhard Bauer - Head Research, Development & Operations
- Wolfgang Becker - Head Distributor & Emerging Markets EMEA
- Robert Woolley - Head Sales North America
- Jens Dexheimer - Head Sales Europe
- Peter Hackel - Chief Financial Officer
- Holger Haderer - Head Customer Solutions & Education
- Patrick Kok-Kien Loh - Head Sales Asia / Pacific
- Alastair Robertson - Global People Management & Development
- Petra Rumpf - Head Dental Service Organizations
- Matthias Schupp - Head Sales Latin America, CEO Neodent
- Dirk Reznik - Head of Digital Business
- Camila Finzi - Head Orthodontics Business Unit
production
Straumann is a company that offers surgical, restorative and regenerative solutions, from bone to crown . The product range includes implants and prosthetic components (secondary parts ) that connect the implant to the visible crown of the replacement tooth . The range is completed by suitable precision instruments and additional components .
In addition, Straumann offers a CAD / CAM-based service for creating dental prosthesis solutions. These can range from single-tooth inlays and crowns to 14-unit bridges in different materials - including high-tech ceramics.
As a complement to the dental implant and restoration system, Straumann manufactures products for the regeneration of oral tissue, either to support implant-based procedures or as an aid to preserving teeth in the context of periodontal treatment.
Straumann manufactures the implants and instruments in Villeret (Switzerland) and Andover (USA), the products for oral tissue regeneration in Malmö (Sweden). The dental restoration products are manufactured in Europe and the USA.
Villeret
The most important components of the “Straumann® Dental Implant System” are manufactured in the Straumann production facility in Villeret, Switzerland. More than 4.5 million parts are manufactured every year.
The Villeret production site went into operation in 2000. The sustained global volume growth made it necessary to expand capacity, so that a second production area was set up in 2005. Since then, two independent production lines have been in operation, one producing surgical products (implants) and the other producing secondary parts for implant prosthetic products. The production line for SLActive , the third-generation implant surface technology , is located in Villeret .
Andover
In Andover, at the North American headquarters, is Straumann's first production facility outside of Switzerland, where components of the implant system and instruments are manufactured.
The 7,400 square meter production area was put into operation in June 2005. It complements the production plant in Villeret and is focused on processing titanium .
Malmo
The regenerative products are manufactured in the production facility in Malmö. In June 2003, Straumann took over the Swedish company Biora, which specializes in the manufacture of Emdogain®, a protein-based product for tissue regeneration.
Markkleeberg
Straumann took over etkon in 2007. The etkon milling center in Markkleeberg near Leipzig produces individual secondary parts for implant prosthetics on its fully automated production lines.
Web links
Individual evidence
- ↑ a b c d Annual Report 2019. Straumann Group, accessed March 1, 2020 .
- ↑ Bernd Remmers: "Unternehmerblut", NZZ Libro, pp. 195ff., ISBN 978-3-03810-364-6 , Zurich 2019